Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis
Status Discontinued
Decision Selected
Process MTA
Topic area
  • Musculoskeletal

Provisional Schedule

Information meeting with consultees: 25 November 2003
Closing date for invited submissions / evidence submission: 03 February 2004
Final scope published: September 2003
1st appraisal committee meeting: 06 October 2004
2nd appraisal committee meeting: TBC

Project Team

Assessment Group / Evidence Review Group: West Midlands Health Technology Assessment Collaboration, University of Birmingham
Communications manager: Tonya Gillis
Executive Lead: Andrew Dillon
Project manager: Cathryn Fuller
Technical Lead: Elisabeth George and Sarah Garner


Manufacturers / Sponsors Boehringer Ingelheim
  Merck Sharp and Dohme
Others Department of Health
  Bolton PCT
  Ashford PCT
  Welsh Assembly Government
Patient / Carer Groups Arthritis and Musculoskeletal Alliance (prev known as the British League Against Rheumatism)
  Arthritis Care
  Arthritis Research Campaign
  British Health Professionals in Rheumatology
  British Institute of Musculoskeletal Medicine
  British Society for Rheumatology
  British Society of Gastroenterology
  Chartered Society of Physiotherapy
  National Rheumatoid Arthritis Society
  Primary Care Rheumatology Society
  Royal College of Nursing
  Royal College of Physicians
  Royal Pharmaceutical Society
  The Royal Association for Disability & Rehabilitation
Professional Groups None
Assessment Team None
Associated Guideline Groups None
Comparator Manufacturers None
General British National Formulary
  Medicines and Healthcare products Regulatory Agency (MHRA)
  National Collaborating Centre for chronic conditions
  National Public Health Service for Wales
  NHS Confederation
  NHS Quality Improvement Scotland
  NHS Purchasing and Supplies Agency
Research Groups Cochrane Upper Gastro-intestinal and Pancreatic Diseases Group


Key events during the development of the guidance:

Date Update
15 December 2004

This review has been suspended pending the outcome of the European Medicines Agency (EMEA) review of cox II inhibitors.

The clarifications requested by the Committee have now been completed, so that the Committee will have a final revised Assessment Report to consider when this topic is considered again. This meeting will be scheduled after the projected date for the issuing of the EMEA recommendations on cox II inhibitors.

In the meantime, the current NICE guidance (no. 27) on this health technology will continue to apply, with the caveat that rofecoxib has been withdrawn from sale by its manufacturers.

For further information on our processes and methods, please see our CHTE processes and methods manual